



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>C12N 15/12, C07K 13/00</b> <b>A61K 37/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/07076</b> <b>(43) International Publication Date:</b> <b>30 April 1992 (30.04.92)</b>
<b>(21) International Application Number:</b> PCT/GB91/01826 <b>(22) International Filing Date:</b> 18 October 1991 (18.10.91)  <b>(30) Priority data:</b> 9022648.1      18 October 1990 (18.10.90)      GB  <b>(71) Applicant (for all designated States except US):</b> THE CHAR- ING CROSS SUNLEY RESEARCH CENTRE [GB/ GB]; 1 Lurgan Avenue, Hammersmith, London W6 8LW (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> FELDMANN, Marc [AU/GB]; The Charing Cross Sunley Research Centre, 1 Lurgan Avenue, Hammersmith, London W6 8LW (GB). GRAY, Patrick, William [US/US]; Icos Corporation, 22021 20th Avenue South East, Bothell, WA 98021 (US). TURNER, Martin, John, Charles [GB/US]; Howard Hughes Medical Institute, University of Michigan Medi- cal Center, 1150 West Medical Campus Drive, Ann Ar- bor, MI 48109 (US). BRENNAN, Fionula, Mary [AU/ GB]; The Charing Cross Sunley Research Centre, 1 Lur- gan Avenue, Hammersmith, London W6 8LW (GB).		<b>(74) Agents:</b> WOODS, Geoffrey, Corlett et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (Eu- ropean patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European pa- tent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> MODIFIED HUMAN TNFALPHA (TUMOR NECROSIS FACTOR ALPHA) RECEPTOR  <div data-bbox="250 1362 1346 1617" data-label="Diagram"> </div>		
<b>(57) Abstract</b> <p>A polypeptide which is capable of binding human TNF<math>\alpha</math> and which consists essentially of: a) the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of the 55kD or 75kD receptor for human TNF<math>\alpha</math>; or b) an amino acid sequence having a homology of 90 % or more with the said sequence (a).</p>		

BEST AVAILABLE COPY

## BEST AVAILABLE COPY

### *FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE <sup>*</sup>	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

<sup>+</sup> Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

- 1 -

Modified human TNF $\alpha$ (Tumor Necrosis Factor alpha) Receptor.

The present invention relates to recombinant proteins and their use.

Tumour necrosis factor- $\alpha$  (TNF $\alpha$ ) is a potent cytokine which elicits a broad spectrum of biological responses. TNF $\alpha$  causes the cytolysis or cytostasis of many tumour cell lines in vitro, induces the haemorrhagic necrosis of transplanted tumours in mice, enhances the phagocytosis and cytotoxicity of polymorphonuclear neutrophils, and modulates the expression of many proteins, including lipoprotein lipase, class I antigens of the major histocompatibility complex, and cytokines such as interleukin 1 and interleukin 6. TNF $\alpha$  appears to be necessary for a normal immune response, but large quantities produce dramatic pathogenic effects. TNF $\alpha$  has been termed "cachectin" since it is the predominant factor responsible for the wasting syndrome (cachexia) associated with neoplastic disease and parasitemia. TNF is also a major contributor to toxicity in gram-negative sepsis, since antibodies against TNF can protect infected animals.

The many activities of TNF $\alpha$  are mediated by binding to a cell surface receptor. Radioligand binding studies have confirmed the presence of TNF receptors on a wide variety of cell types. Although these receptors are expressed in limited numbers (1,000 - 10,000 receptors/cell), they bind TNF $\alpha$  with high affinity ( $K_a = 10^9 M^{-1}$  at 4°C). Lymphotoxin (LT, also termed TNF $\beta$ ) has similar, if not identical, biological activities to TNF $\alpha$ , presumably because both are recognized by the same receptor.

Recently, several laboratories have detected heterogeneity in TNF receptor preparations. Two distinct cell surface receptors which bind TNF $\alpha$  and TNF $\beta$  have recently been characterised at the molecular level. cDNA for one form of the receptor with a Mr of 55kD was isolated utilising probes designed from the peptide sequence of a

BEST AVAILABLE COPY

- 2 -

BEST AVAILABLE COPY

soluble form of the receptor (1,2). A second receptor of Mr 75kD was cloned by a COS cell expression approach (3). Both receptors are members of a larger family of cytokine receptors which include the nerve growth factor receptor, the B cell antigen CD40, the rat T cell antigen MRC OX40. In addition these receptors are homologous to the predicted product of a transcriptionally active open reading frame from Shope fibroma virus which appears to give rise to a secreted protein.

10 The most conserved feature amongst this group of cell surface receptors is the cysteine rich extracellular ligand binding domain, which can be divided into four repeating motifs of about forty amino acids. We have now generated four soluble receptor derivatives of the 55kD TNF $\alpha$  receptor (TNFR). Each derivative is composed of the extracellular binding domain but without one of the cysteine rich subdomains. We have found that the derivative which lacks the membrane-proximal fourth subdomain retains the ability to bind TNF $\alpha$  with high affinity. This finding has general applicability.

Accordingly, the present invention provides a polypeptide which is capable of binding human TNF $\alpha$  and which consists essentially of:

- (a) the first three cysteine-rich subdomains, but not the fourth cysteine-rich subdomain, of the extracellular binding domain of the 55kD or 75kD receptor for human TNF $\alpha$ ; or
- (b) an amino acid sequence having a homology of 90% or more with the said sequence (a).

30 The invention also provides:

- a DNA sequence which encodes such a polypeptide;
- a vector which incorporates a DNA sequence of the invention and which is capable, when provided in a transformed host, of expressing the polypeptide of the invention encoded by the DNA sequence; and

- 3 -

a host transformed with such a vector.

In the accompanying drawings:

Figure 1 shows the nucleotide sequence of the human TNF $\alpha$  cDNA and encoded amino acid sequence. The predicted signal sequence residues are numbered -40 to -1. The transmembrane domain is boxed and potential N-linked glycosylation sites are overlined. The sequence homologous with the designed oligonucleotide probe is found at nucleotide positions 477-533.

10 Figure 2 is a Northern blot (lanes 1-3) of 10 $\mu$ g of oligo-dT selected RNA from human 293 cells (fibroblast cell line) (lane 1), placenta (lane 2) and spleen (lane 3) hybridised with the TNF receptor cDNA (SmaI-EcoRI fragment). The Southern blot (lanes 4-6) was hybridized  
15 with the same probe. Human genomic DNA (5  $\mu$ g per lane) was digested with PstI (lane 4), Hind III (lane 5) and EcoRI (lane 6).

Figure 3 shows the binding characteristics of recombinant human TNF receptor expressed in COS-7 cells.  
20 The direct binding of recombinant  $^{125}$ I-TNF $\alpha$  to COS-7 cells transfected with prTNFR is presented in panel A. The inset contains Scatchard analysis derived from this data. As shown in panel B, monolayers of Cos-7 cells transfected with TNFR cDNA were incubated with 1nM  $^{125}$ I-TNF in the  
25 presence of various concentrations of unlabelled TNF $\alpha$  or TNF $\beta$ .

Figure 4 shows the effects of soluble TNFR on TNF $\alpha$  binding and biological activity. Panel A shows the effects of supernatants from Cos-7 cells transfected with a cDNA  
30 encoding a soluble form of the TNF receptor (pTNFR $\alpha$ cd, closed circles) or mock transfected (open circles) on  $^{125}$ I-TNF binding to U937 cells. Panel B shows the effects of these supernatants on TNF mediated killing of WEHI 164 (clone 13) line. Assays were performed as described in  
35 Materials and Methods.

- 4 -

Figure 5 is a diagram of the DNA sequence of pTNFRecd and is also a strategy map for polymerase chain reaction (PCR)-based domain deletion, in which 5'UTR is the 5'-untranslated region and I to IV are the four cysteine-rich subdomains. The oligonucleotides employed in PCR in the Example and relevant restriction sites are also shown.

Figure 6 shows lined up the amino acid sequences of the four cysteine-rich subdomains of the 55kD (TNFR-55) and 75kD (TNFR-75) receptors and of rat nerve growth factor receptor (NGFR), human CD40 and rat OX40. Homology is shown by means of boxes.

Figures 7 to 11 show the nucleotide sequence and the predicted amino acid sequence of the encoded polypeptide of pTNFRecd, p $\Delta$ I, p $\Delta$ II, p $\Delta$ III and p $\Delta$ IV.

Figure 12 shows the results of the assays described in the Example 1.

Figure 13 shows diagrammatically the DNA encoding the 75kD receptor in which I to IV are the four cysteine-rich subdomains. Oligonucleotides employed in PCR-domain deletion are also shown.

A polypeptide according to the invention is capable of binding human TNF $\alpha$ . Typically the polypeptide has a binding affinity for human TNF $\alpha$  of  $10^7 \text{M}^{-1}$  or greater, for example  $10^8 \text{M}^{-1}$  or greater. The affinity may be from  $10^7$  to  $10^{10} \text{M}^{-1}$ , for example from  $10^8$  to  $10^9 \text{M}^{-1}$ .

A preferred polypeptide consists essentially of the first three cysteine-rich subdomains of the extracellular binding domain of the 55kD receptor for human TNF $\alpha$ . The sequence (a<sub>1</sub>) of these three subdomains is:

	V	C	P	Q	G															
30	K	Y	I	H	P	Q	N	N	S	I	C	C	T	K	C	H	K	G	T	Y
	L	Y	N	D	C	P	G	P	G	Q	D	T	D	C	R	E	C	E	S	G
	S	F	T	A	S	E	N	H	L	R	H	C	L	S	C	S	K	C	R	K
	E	M	G	Q	V	E	I	S	S	C	T	V	D	R	D	T	V	C	G	C
	R	K	N	Q	Y	R	H	Y	W	S	E	N	L	F	Q	C	F	N	C	S
35	L	C	L	N	G	T	V	H	L	S	C	Q	E	K	Q	N	T	V	C	.

- 5 -

A useful polypeptide has the amino acid sequence (c):

```

M G L S T V P D L L L P L V L L E L L V
G I Y P S G V I G L V P H L G D R E K R
D S V C P Q G K Y I H P Q N N S I C C T
5 K C H K G T Y L Y N D C P G P G Q D T D
C R E C E S G S F T A S E N H L R H C L
S C S K C R K E M G Q V E I S S C T V D
R D T V C G C R K N Q Y R H Y W S E N L
F Q C F N C S L C L N G T V H L S C Q E
10 K Q N T V C T.

```

In an alternative embodiment, the polypeptide may consist essentially of the first three cysteine-rich subdomains of the extracellular binding domain of the 75kD receptor.

15 Apart from the amino acid sequence (a), the polypeptides may alternatively consist essentially of an amino acid sequence (b) having a homology of 90% or more with sequence (a). The degree of homology may be 95% or more or 98% or more. Amino acid sequence (a) may therefore be modified by  
 20 one or more amino acid substitutions, insertions and/or deletions and/or by an extension at either or each end. There should be no modification of the cysteine-residues, however. A polypeptide comprising sequence (b) must of course still be capable of binding human TNF $\alpha$ .

25 For example, one or more amino acid residues of the sequence (a), other than a cysteine residue, may be substituted or deleted or one or more additional amino acid residues may be inserted; provided the physicochemical character of the original sequence is preserved, i.e. in  
 30 terms of charge density, hydrophobicity/hydrophilicity, size and configuration. Conservative substitutions may be made. Candidate substitutions are, based on the one-letter code (Eur. J. Biochem. 138, 9-37, 1984):

35 A for G and vice versa,

- 6 -

V by A, L or G;

K by R;

S by T and vice versa;

E for D and vice versa; and

5 Q by N and vice versa.

Up to 15 residues may be deleted from the N-terminal and/or C-terminal of the polypeptide, for example up to 11 residues or up to 5 residues.

The polypeptides of the invention consist essentially of  
10 sequence (a) or (b). They do not contain a fourth cysteine-rich subdomain. However, the polypeptides may be longer polypeptides of which sequence (a) or (b) is a part. A short sequence of up to 50 amino acid residues may be provided at either or each terminal of sequence (a) or (b).  
15 The sequence may have up to 30, for example up to 20 or up to 10, amino acid residues.

Alternatively, a much longer extension may be present at either or each terminal of sequence (a) or (b) of up to, for example, 100 or 200 amino acid residues. Longer amino  
20 acid sequences may be fused to either or each end. A chimaeric protein may be provided in which the or each extension is a heterologous amino acid sequence, i.e. a sequence not naturally linked to the amino acid sequence above. Such a chimaeric protein may therefore combine the  
25 ability to bind specifically to human TNF $\alpha$  with another functionality.

The polypeptides of the invention lack the fourth cysteine-rich subdomain of the 55kD or 75kD receptor as the case may be. In particular, they lack the cysteine  
30 residues of the fourth subdomain. They therefore do not comprise, immediately after the third cysteine-rich subdomain, any of the amino acid sequence up to the last cysteine residue of the fourth cysteine-rich subdomain of the relevant receptor except possibly the first amino acid  
35 residue of that sequence. The polypeptides may extend



- 8 -

TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT  
CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC  
TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC  
TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC  
5 ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC  
CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC  
CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG  
AAC ACC GTG TGC ACC.

A DNA sequence encoding a polypeptide of the invention  
10 may be synthesised. Alternatively, it may be constructed  
by isolating a DNA sequence encoding the 55kD or 75kD  
receptor from a gene library and deleting DNA downstream of  
the coding sequence for the first three cysteine-rich  
subdomains of the extracellular binding domain of the  
15 receptor. This gives DNA encoding the first three  
subdomains of either receptor. As an intermediate step,  
DNA encoding the entire or nearly the entire extracellular  
binding domain may be isolated and digested to remove DNA  
downstream of the coding sequence for the first three  
20 subdomains.

A modified nucleotide sequence, for example encoding an  
amino acid sequence (b), may be obtained by use of any  
appropriate technique, including restriction with an  
endonuclease, insertion of linkers, use of an exonuclease  
25 and/or a polymerase and site-directed mutagenesis. Whether  
a modified DNA sequence encodes a polypeptide of the  
invention can be readily ascertained. The polypeptide  
encoded by the sequence can be expressed in a suitable host  
and tested for its ability to bind specifically human TNF $\alpha$ .

30 For expression of a polypeptide of the invention, an  
expression vector is constructed. An expression vector is  
prepared which comprises a DNA sequence encoding a  
polypeptide of the invention and which is capable of  
expressing the polypeptide when provided in a suitable  
35 host. Appropriate transcriptional and translational

- 9 -

control elements are provided, including a promoter for the DNA sequence, a transcriptional termination site, and translational start and stop codons. The DNA sequence is provided in the correct frame such as to enable expression  
5 of the polypeptide to occur in a host compatible with the vector.

The expression vector is then provided in an appropriate host. Cells harbouring the vector are grown so as to enable expression to occur. The vector may be a plasmid or  
10 a viral vector. Any appropriate host-vector system may be employed.

The transformed host may be a prokaryotic or eukaryotic host. A bacterial or yeast host may be employed, for example E. coli or S. cerevisiae. Insect cells can  
15 alternatively be used, in which case a baculovirus expression system may be appropriate. As a further alternative, cells of a mammalian cell line, such as Chinese Hamster Ovary (CHO) Cells may be transformed. A polypeptide glycosylated at one, two or three of the sites  
20 shown in Figure 1 can be obtained by suitable choice of the host cell culture.

The polypeptide of the invention can be isolated and purified. The N-terminal of the polypeptide may be heterogeneous due to processing of the translation product  
25 within a cell or as the product is being secreted from a cell. A mixture of polypeptides according to the invention, having different N-termini, may therefore be obtained. The polypeptide is soluble.

The polypeptides of the invention have activity binding  
30 human TNF $\alpha$ . This activity is indicative of the possible use of the polypeptides in the regulation of TNF $\alpha$ -mediated responses by binding and sequestering human TNF $\alpha$ , for example possible use in treatment of pulmonary diseases, septic shock, HIV infection, malaria, viral meningitis,  
35 graft versus host reactions and autoimmune diseases such as

- 10 -

rheumatoid arthritis.

For this purpose, a polypeptide of the present invention may be formulated in a pharmaceutical composition. The pharmaceutical composition also comprises a  
5 pharmaceutically acceptable carrier or diluent.

The polypeptide of the invention may be administered to a patient by any convenient route. The choice of whether an oral route or a parenteral route, such as subcutaneous, intravenous or intramuscular administration, is adopted; of  
10 the dose; and of the frequency of administration depends upon a variety of factors. These factors include the purpose of the administration, the age and weight of the patient being treated and the condition of the patient. Typically, however, the polypeptide is administered in an  
15 amount of from 1 to 1000  $\mu$ g per dose, more preferably from 10 to 100  $\mu$ g per dose, for each route of administration.

The following Examples illustrate the invention. A Reference Example is provided.

#### REFERENCE EXAMPLE

##### 20 1. Materials and Methods

###### Reagents

Recombinant human TNF $\alpha$  and TNF $\beta$  were supplied as highly purified proteins derived from *E. coli*. The specific activities of these preparations were approximately 10<sup>7</sup>  
25 units/mg, as measured in the murine L929 cell cytotoxicity assay (4). The synthetic oligonucleotides were prepared by Oswel DNA Service (University of Edinburgh).

###### Isolation of TNF $\alpha$ 55kD receptor cDNA clones

The sequence of a peptide fragment (E M G Q V E I S S T  
30 V D R D T V C G) of the TNF binding protein was used to design a synthetic oligonucleotide probe (5' AAG GAG ATG GGC CAG GTT GAG ATC TCT TCT ACT GTT GAC AAT GAC ACT GTG TGT GGC-3'). The 57-mer DNA probe was labelled with <sup>32</sup>P and T4

- 11 -

- polynucleotide kinase (New England Biolab, Beverly, MA) and used to screen a placenta cDNA library in gt10 (5,6). Approximately 800,000 phage were transferred to nitrocellulose filters and screened at reduced stringency
- 5 (7). Filters were incubated for 2 hours at 42°C in 0.05M sodium phosphate, pH 6.5, 20% formamide, 0.75 M sodium chloride, 0.075 M sodium citrate, 1% polyvinyl pyrrolidone (Sigma, St Louis, MO), 1% Ficoll, 1% bovine serum albumin (Sigma), and 50 ng/ml sonicated salmon sperm DNA (Sigma).
- 10 The radiolabelled probe was then added to the filters ( $10^8$  cpm/ml final concentration) which were hybridized for 16 hours. Filters were washed extensively in 0.06M sodium chloride, 0.006M sodium citrate, 1% SDS at 37°C and positive clones were identified by autoradiography. Ten
- 15 hybridizing clones were plaque purified (5) and cDNA insert size was determined by polyacrylamide gel electrophoresis of EcoRI digested phage DNA. The inserts of two cDNA clones were sequenced using the dideoxy chain termination technique (8).
- 20 Southern and Northern blot analysis
- DNA was isolated from human lymphocytes by the method of Blin and Stafford (9) and used for Southern blot analysis (10). DNA was digested with restriction endonucleases (New England Biolabs), fractionated on a 1% agarose gel, and
- 25 transferred to nitrocellulose. Hybridization and washing were conducted under stringent conditions (6) using a  $^{32}\text{P}$ -labelled preparation of a 600 bp fragment of the TNF receptor cDNA. Northern blot analysis was performed (11) on oligo-dT selected RNA isolated from human placenta,
- 30 spleen (generously provided by the Cooperative Human Tissue Network, Birmingham, AL) and a fibroblast cell line (293 cells). Following electrophoresis on a formaldehyde 1.2% agarose gel, the RNA was transferred to nitrocellulose and hybridized with the TNF $\alpha$  receptor DNA probe under stringent
- 35 conditions.

- 12 -

Mammalian cell expression of the human TNF $\alpha$  55kD  
receptor and derivatives

The coding region of the majority of the human TNF $\alpha$  55kD receptor was isolated as an EcoRI fragment and cloned into  
5 a mammalian cell expression vector (12), resulting in  
plasmid prTNFR. The EcoRI fragment encodes 374 amino acids  
of the TNF receptor; the 81 carboxyl terminal residues of  
the cytoplasmic domain are therefore missing from this  
plasmid construction. A derivative of the TNF $\alpha$  receptor  
10 was produced by engineering a termination codon just prior  
to the transmembrane domain. The polymerase chain reaction  
(PCR) technique (13) was used to generate a 300 bp  
restriction fragment containing a BgIII site at the 5' end  
and a HindIII site preceded by a TAG stop codon at the 3'  
15 end. The PCR primers were 5'GCTGCTCCAAATGCCGAAAG and  
5'AGTTCAAGCTTTTACAGTGCCCTTAACATTCTAA.

The PCR product was gel purified and cloned into the TNF  
receptor expression plasmid (described above) digested with  
BgIII and HindIII. DNA sequencing confirmed that the  
20 resulting plasmid (pTNFRecd) contained the designed DNA  
sequence. E. coli harbouring pTNFRecd were deposited at  
the National Collection of Industrial and Marine Bacteria,  
Aberdeen, GB on 11 September 1990 under accession number  
NCIMB 40315.

25 The TNF $\alpha$  receptor expression plasmids were transfected  
into monkey COS-7 cells using Lipofectin (Gibco BRL,  
Bethesda, MD) according to the manufacturer's instructions.  
Cells were cultured in Dulbecco's modified Eagle's medium  
containing 10% fetal calf serum.

30 Analysis of recombinant TNF $\alpha$  55kD receptor derivatives

TNF $\alpha$  was radioiodinated with the Iodogen method (Pierce)  
according to the manufacturer's directions. The specific  
activity of the  $^{125}\text{I}$ -TNF $\alpha$  was 10-30  $\mu\text{Ci}/\mu\text{g}$ . COS cells

- 13 -

transfected with the TNF $\alpha$  receptor cDNA (prTNFR, 1300 bp EcoRI fragment) were incubated for 24 hours and then seeded into six well tissue culture plates (Nunc) at  $4.5 \times 10^8$  cells per well. The cells were incubated for a further 48 hours and then receptor expression was quantitated by radioligand binding for 2 hours at 4°C. Non-specific binding of  $^{125}\text{I}$ -TNF $\alpha$  was determined in the presence of a 1,000 fold molar excess of unlabelled TNF $\alpha$ . Binding data was analysed by the method of Scatchard (14).

10 The TNF $\alpha$  receptor derivative was analysed for inhibition of  $^{125}\text{I}$ -TNF $\alpha$  binding to the natural receptor on human U937 cells. Culture supernatant was harvested 72 hours after COS cells were transfected with pTNFRecd. U937 cells ( $2 \times 10^8$  cells in 200  $\mu\text{l}$ ) were incubated with 1nM  $^{125}\text{I}$ -TNF $\alpha$  and  
15 dilutions of COS cell media for 2 hours at 4°C. Cells were then centrifuged through 20% sucrose to remove unbound TNF $\alpha$ . Non-specific binding was determined in the presence of 1 $\mu\text{M}$  unlabelled TNF $\alpha$ .

The TNF $\alpha$  receptor derivative was also analyzed for  
20 inhibition of TNF $\alpha$  cytotoxic effects in vitro. The cytotoxicity assay was performed as described on the TNF sensitive cell line WEHI 164 clone 13 (15). Serial dilutions of supernatants from COS cells transfected with pTNFRecd or mock transfected controls were incubated with a  
25 constant amount of TNF $\alpha$  (1 ng/ml) for 1 hour at 27°C before addition to the assay.

## 2. RESULTS

### Isolation and characterization of the TNF $\alpha$ 55kD receptor cDNA

30 A partial amino acid sequence of the TNF binding protein was used to design a synthetic oligonucleotide probe. The radiolabelled probe was used to screen a human placenta cDNA library in  $\lambda$ mbdagt10 and ten hybridizing phage were isolated. The nucleotide and deduced amino acid sequences

- 14 -

of the longest cDNA clone are depicted in Figure 1. The third potential ATG initiation codon occurs at position 156 of the nucleotide sequence; the first two ATG codons are closely followed by termination codons, and the third ATG is preceded by the best translation initiation consensus nucleotides (16). The cDNA encodes an open reading frame of 1365 bases which codes for a polypeptide of 455 residues. Both of the peptide sequences determined by amino acid sequencing were identified in the encoded cDNA (17 of 19 and 18 of 19 matching residues). The amino terminal end identified for the TNF binding protein corresponds to the cDNA encoded sequence beginning at residue 41. The first 35 amino acids are generally quite hydrophobic and probably represent a signal sequence. Residues 35-40 are highly charged (DREKR) and such a sequence is not typically found in secretory signal sequences (17); perhaps the natural receptor is processed by proteolysis after residue 40 which contains a dibasic cleavage site (KR). Hydropathy analysis of the protein sequence predicts a single transmembrane domain of 23 amino acids. This hydrophobic sequence divides the protein into an extracellular domain of 171 residues and a cytoplasmic domain of 221 residues. The amino acid composition determined for the TNF binding protein corresponds well with the predicted composition of the extracellular domain encoded by the cDNA (results not shown). The discrepancy between the predicted receptor size (40,000 daltons) and the size determined by SDS-polyacrylamide gel electrophoresis (65,000 daltons, 18-20) is probably due to glycosylation; there are four potential N-linked glycosylation sites in the sequence, three of which are in the extracellular domain. The sequence contains a large number (17) of cysteine residues, 24 of which are in the extracellular domain. The arrangement of these cysteine residues is similar to that of several other cell surface

- 15 -

proteins, suggesting that the TNF receptor is structurally related to a family of receptors.

A Northern blot analysis is presented in Figure 2. The <sup>32</sup>P-labelled cDNA hybridized to a single predominant band of oligo-dT selected RNA from human placenta or spleen. A minor larger transcript was also observed in RNA from a fibroblast cell line. The size of the hybridizing species is 2400 bases, in good agreement with the size of isolated cDNA. Also shown in Figure 2 is a Southern blot of human genomic DNA hybridized with a 600 bp probe from the cDNA. In each of the three different restriction digests, only a single hybridized signal was observed. Thus the TNF receptor that we have isolated appears to be encoded by a single gene.

15

#### Expression of recombinant TNF receptor sequences in mammalian cells

To confirm that the cDNA shown in Figure 1 indeed encodes the TNF receptor, the cDNA was engineered for expression in mammalian cells. The cDNA contains an EcoRI site at position 1270 of Figure 1. The receptor coding sequence was isolated as a 1300 bp EcoRI-fragment (containing all but the last 81 codons of the cytoplasmic domain) and inserted into a mammalian cell expression vector containing a cytomegalovirus promoter and SV40 transcription termination sequences (12). The resulting plasmid was transfected into COS cells which were analyzed for TNF receptor expression after three days. As shown in Figure 3, the transfected cells specifically bound radioiodinated TNF $\alpha$  in a saturable and dose dependent fashion. The population of COS cells expressed approximately  $1 \times 10^8$  receptors per cell. The measured binding affinity of recombinant receptors was  $2.5 \times 10^9 \text{ M}^{-1}$  at 4°C which is in close agreement with natural receptor on human cells (19,20). The binding of <sup>125</sup>I-TNF $\alpha$  (1 nM) to



- 16 -

these cells could be inhibited by the addition of unlabelled TNF $\alpha$  or lymphotoxin (Figure 3b). COS cells transfected with just the expression vector did not significantly bind  $^{125}\text{I}$ -TNF $\alpha$  (less than 2% of the binding  
5 seen with the cDNA transfection).

The extracellular domain of the TNF receptor is naturally shed from cells. To produce a similar recombinant derivative, a stop codon preceding the transmembrane domain was engineered into the cDNA by PCR  
10 mutagenesis. The modified DNA was inserted into the expression plasmid and subsequently transfected into COS cells. After three days, the COS cell media was tested for inhibition of TNF $\alpha$  binding to human U937 cells. As shown in Figure 4a, the transfected cell media inhibited up to  
15 70% of the binding of TNF $\alpha$ . The recombinant TNF receptor derivative was next tested for inhibition of TNF $\alpha$  biological activity. A sensitive bioassay for TNF $\alpha$  is a measurement of cytolysis of mouse WEHI 164 (clone 13) cells. The transfected cell media inhibited 60% of TNF $\alpha$   
20 cytotoxicity on this cell line (Figure 4b). Media from mock transfected COS cells did not inhibit TNF $\alpha$  induced cytotoxicity or binding. These experiments demonstrate that the recombinant extracellular domain of the TNF receptor is capable of binding TNF and inhibiting its  
25 biological activity.

EXAMPLE 1: Expression of polypeptide consisting essentially of the first three cysteine-rich subdomains of the extracellular binding domain of the 55kD receptor

1. MATERIALS AND METHODS

30 Reagents

E. coli derived recombinant human TNF $\alpha$  had a specific activity of  $2 \times 10^7$  U/mg in an L929 cytotoxicity assay. Oligonucleotides were purchased from Oswel DNA service (University of Edinburgh).

- 17 -

Generation of the recombinant soluble TNFR derivatives

Deletion of each of the subdomains in the recombinant soluble TNFR was achieved by means of PCR fragment joining and PCR mutagenesis. The sequence of the oligonucleotides used in these experiments is given in Table 1 and their locations relative to the four cysteine rich subdomains is shown in Figure 5. The four subdomains are lined up with respect to one another in Figure 6.

The plasmid pTNFRecd (Reference Example) is shown in Figure 7. pTNFRecd was further modified to remove 5' untranslated sequences by cloning of the Cla I/Bgl II digested product of a PCR using oligos 5' Cla and IIIA into ClaI/Bgl II digested pTNFRecd, to generate 5'- $\Delta$  Cla. Digestion of 5'- $\Delta$  Cla with Pst-1 and religation resulted in the generation of p $\Delta$ II, which lacks the second cysteine rich subdomain (Figure 9). The fourth cysteine rich subdomain was removed by cloning of the BglII/Hind III digested product of a PCR using oligonucleotides 5A and 4D into BglII/Hind III 5'- $\Delta$  Cla; this introduced a termination codon after amino acid 167 (counting from the initial methionine) to yield p $\Delta$ IV (Figure 11). The constructs p I (Figure 8) and p $\Delta$ III (Figure 10) which lack the first and third cysteine rich subdomains respectively were generated by joining PCR fragments by means of overlaps introduced into the primers used for the PCR. The gel purified products of PCR's using 5' Cla and IA and IB and 5D were mixed and subjected to further amplification using 5' Cla and 5D as primers. The resulting fragment was digested with ClaI and BglII and cloned into ClaI/BglII digested pTNFRecd, to yield p $\Delta$ I.

Similarly the gel purified products of PCR's using 5' Cla and IIIA and IIIb and 5D were mixed and subjected to further amplification using 5' Cla and 5D as primers. This product was digested with BglII and HindIII and cloned into Bgl II/Hind III cut 5'- $\Delta$  Cla to yield p $\Delta$ III. In all cases

- 18 -

the cloned derivatives were analysed by restriction enzyme analysis and DNA sequencing using sequenase (United States Biochemical Corporation).

**Table 1: Structure of the mutagenic oligonucleotides**

5	Oligo	Sequence
	<u>Name</u>	
	5'Cla	5'-GTTCTATCGATAAGAGGCCATAGCTGTCTGGC-3'
	IA	5'-GCTCTCACACTCTCTCTTCTCCCTGTCCCCTAG-3'
	IB	5'-AGGGAGAAGAGAGAGTGTGAGAGCGGCTCCTTC-3'
10	IIIA	5'-TGCATGGCAGGTACACACGGTGTCCCGGTCCAC-3'
	IIIB	5'-GACACCGTGTGTACCTGCCATGCAGGTTTCTTT-3'
	4D	5'-GGCCAAGCTTCAGGTGCACACGGTGTTCG-3'
	5A	5'-GCTGCTCCAAATGCCGAAAG-3'
	5D	5'-AGTTCAAGCTTTACAGTGCCCTTAACATTCTAA-3'

#### 15 Analysis of recombinant soluble TNFR derivatives

COS cells were maintained in Dulbecco's modified Eagles medium containing 5% foetal calf serum. The soluble TNF $\alpha$  receptor derivatives were transfected into monkey COS cells by means of lipofectin (GIBCO-BRL, Bethesda MD) according to the manufacturers protocol and cell free supernatants harvested 72 hours post transfection.

#### Inhibition of TNF $\alpha$ activity

The soluble TNF $\alpha$  receptor derivatives were analyzed for inhibition of TNF $\alpha$  cytotoxic activity in vitro. The cytotoxicity assay was performed as described on the TNF $\alpha$  sensitive cell line WEHI 164 clone 13. Serial dilutions of supernatants from COS cells transfected with the mutant receptors or mock transfected controls were incubated with a constant amount of TNF (1 ng/ml) for 1 hour at 37°C before addition to the assay.

## 2. RESULTS

In order to understand more about the contribution of

- 19 -

the individual cysteine rich subdomains to the binding of TNF $\alpha$  by the soluble form of the 55kD TNF receptor, we removed each subdomain by PCR mutagenesis (Figure 5). COS cells were transfected with each of these constructs and the supernatants were assayed for their ability to inhibit the cytotoxic activity of TNF $\alpha$ . Figure 12 panel A shows that conditioned medium from COS cells transfected with pTNFRecd inhibits TNF $\alpha$  as previously described. Removal of the fourth cysteine rich subdomain resulted in a protein which, similar to TNFRecd, was a potent inhibitor of TNF $\alpha$  (Figure 12 panel B). The mutants lacking the first, second and third subdomains did not show any inhibitory activity in the TNF $\alpha$  cytotoxicity assay.

EXAMPLE 2: Expression of polypeptide consisting essentially of the first three cysteine-rich subdomains of the extracellular binding domain of the 75kD receptor.

The coding region of the human 75kD TNF $\alpha$  receptor was isolated from a T cell lambda ZAP library, using a probe based on published sequences (3) and cloned into the EcoRI site of a mammalian cell expression vector (12) resulting in plasmid p75TNFR. In more detail, RNA was extracted from a cell line expressing the 75kD receptor and reverse transcribed. Any cell line expressing this receptor could be used, such as those described by Smith *et al* (3). The product of the reverse transcription was subjected to 25 cycles of PCR using the following primers:

5' CGC AGA ATT CCC CGC AGC CAT GGC GCC CGT CGC C 3'

and 5' GTA AGG ATC CTA TCG CCA GTG CTC CCT TCA GCT 3'.

These primers are directed against the extracellular binding domain coding region of the 75kD receptor and were taken from Smith *et al* (3). The amplified product was gel purified and shown to encode TNFR. This was subsequently used to screen the library. Plaque purification was performed essentially as described in the Reference Example

- 20 -

except that the probe was labelled by random priming (21) and hybridised in 50% formamide. Filters were washed in 0.2 x SSC (Standard Saline Citrate) twice at 60°C.

5 A derivative of the 75kD TNF $\alpha$  receptor was produced by engineering a termination codon just prior to the transmembrane domain. Referring to Figure 13, the polymerase chain reaction (PCR) technique was used to generate a 274 bp restriction fragment containing a BglII site at the 5' end and an Xba I site preceded by a TAG stop  
10 codon at the 3' end. The PCR primers were 5' ACACGACTTCATCCACGGATA and 5'ACGTTCTAGACTAGTCGCCAGTGCTCCCTTCAGCTG. The PCR product was digested with Bgl II and Xba I, gel purified and cloned into the TNF receptor expression plasmid (described above)  
15 digested with BglII and Xba I. DNA sequencing confirmed that the resulting plasmid contained the designed DNA sequence.

A similar approach was utilised to generate a construct which lacked the fourth cysteine-rich subdomain of the 75kD  
20 TNF $\alpha$  receptor. PCR was performed using a primer upstream of the Esp I site in the 75kD TNFR and a primer which introduced a TAG termination codon and an Xba I site. The sequences of the primers was 5' CAG AAC CGC ATC TGC ACC TGC and 5'ACGTTCTAGACTTGACACACCACGTCTGATGTTTC respectively. The  
25 PCR product was digested with EspI and Xba I and the 110bp DNA fragment gel purified and cloned into Esp I Xba I digested p75TNFR.

- 21 -

REFERENCES

1. Loetscher, H., Pan, Y.-C.E., Lahm, H.-W., Gentz, R., Brockhaus, M., Tabuchi, H. and Lesslayer, W. (1990) Cell, 61, 351-359.
- 5 2. Schall, T.J., Lewis, M., Koller, K.J., Lee, A., Rice, G.C., Wong, G.H.W., Gatanaga, T., Granger, G.A., Lentz, R., Raab, H., Kohl, W.J. and Goeddel, D.Y. (1990) Cell, 61, 361-370.
3. Smith, C.A., Davis, T., Anderson, D., Solam, L.,  
10 Beckmann, M.P., Jerzy, R., Dower, S.K., Cosman, D. and Goodwin, R.G. (1990) Science 248, 1019-1023.
4. Ruff, M.R. & Gifford, G.E. (1981) Infection and Immunity, 31, 380.
5. Maniatis, T., Hardison, R.C., Lacy, E., Lauer, J.,  
15 O'Connell, C., Quon, D., Sim, G.K. and Efstratiadis, A. (1978) Cell 15, 687-701.
6. Lawn, R.M., Fritsch, E.F., Parker, R.C., Blake, G & Maniatis, T. (1978) Cell 15, 1157-1174.
7. Gray, P.W., Leong, S.R., Fennie, E., Farrar, M.A.,  
20 Pingel, J.T. and Schreiber, R.D. (1989) Proc. Natl. Acad. Sci USA 86, 8497-8501.
8. Smith, A.J.H., (1980) Meth. Enzym. 65 560-580.
9. Blin, N, & Stanford, D.W. (1976) Nucl. Acids Res. 3, 2303-2398.
- 25 10. Southern, E.M. (1975) J. Molec. Biol. 98, 503-517.
11. Dobner, P.R., Kawasaki, E.S., Yu, L.Y. and Bancroft, F.C. (1981) Proc. Natl. Acad. Sci. USA. 78, 2230-2234.
12. Eaton, D.L., Wood, W.I., Eaton, D., Hass, P.E., Hollinghead, P., Wion, K., Mather, J., Lawn, R.M.,  
30 Vahar, G.A. and Gorman, C. (1986) Biochemistry 25: 8343-8347.
13. Scharf, S.J., Horn, G.T., Erlich, H.A. (1986) Science 233, 1076-1079.
14. Scatchard, G. (1949) Ann. New York Acad. Sci. 51, 660-  
35 672.

- 22 -

15. Espevik, T. & Nissen-Meyer, J. (1986) J. Immunol. Meths. 95, 99-105.
16. Kozak, M. (1989) J. Cell. Biol. 108, 229-241.
17. von Heijne, G. (1988) Nucl. Acids. Res. 14, 4683-4690.
- 5 18. Creasy, A.A., Yamamoto, R. & Vitt, C.R. (1987) Proc. Natl. Acad. Sci. USA. 84, 3293-3297.
19. Stauber, G.B., Alyer, R.A. & Aggarwal, B.B. (1988) J. Biol. Chem. 263, 19098-19104.
20. Scheurich, P., Ucer, U., Kronke, M. and Pfitzenmaier, K. (1986) Int. J. Cancer, 38, 127-133.
- 10 21. Feinburg, A. & Vogelstein, B (1984) Analytical Biochem. 137, 266-277.

- 23 -

CLAIMS

1. A polypeptide which is capable of binding human TNF $\alpha$  and which consists essentially of:
  - (a) the first three cysteine-rich subdomains, but not the
  - 5 fourth cysteine-rich subdomain, of the extracellular binding domain of the 55kD or 75kD receptor for human TNF $\alpha$ ; or
  - (b) an amino acid sequence having a homology of 90% or more with the said sequence (a).
- 10 2. A polypeptide according to claim 1, which consists essentially of the first three cysteine-rich subdomains of the extracellular binding domain of the 55kD receptor for human TNF $\alpha$ .
3. A polypeptide according to claim 2, which has the
- 15 amino acid sequence: M G L S T V P D L L L P L  
 V L L E L V G I Y P S G V I G L V P H L  
 G D R E K R D S V C P Q G K Y I H P Q N  
 N S I C C T K C H K G T Y L Y N D C P G  
 P G Q D T D C R E C E S G S F T A S E N  
- 20 H L R H C L S C S K C R K E M G Q V E I  
 S S C T V D R D T V C G C R K N Q Y R H  
 Y W S E N L F Q C F N C S L C L N G T V  
 H L S C Q E K Q N T V C T.
4. A DNA sequence which encodes a polypeptide as
- 25 defined in any one of the preceding claims.
5. A DNA sequence according to claim 4, which comprises:
 

GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT  
 TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT  
- 30 CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC  
 TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC  
 TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC  
 ACA GTG GAC CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC  
 CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC



- 24 -

CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG  
AAC ACC GTG TGC.

6. A DNA sequence according to claim 4 or 5, which  
further comprises a 5' sequence which encodes a signal  
5 amino acid sequence.

7. A DNA sequence according to claim 4, which is:  
ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCG CTG GTG CTC  
CTG GAG CTG TTG GTG GGA ATA TAC CCC TCA GGG GTT ATT GGA CTG  
GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT CCC  
10 CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC  
AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG  
GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC  
GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC AGC TGC TCC AAA TGC  
CGA AAG GAA ATG GGT CAG GTG GAG ATC TT TCT TGC ACA GTG GAC  
15 CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT  
TGG AGT GAA AAC CTT TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC  
AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG  
TGC ACC.

8. A vector which incorporates a DNA sequence as  
20 claimed in any one of claims 4 to 7 and which is capable,  
when provided in a suitable host, of expressing the said  
polypeptide.

9. A vector according to claim 8, which is a  
plasmid.

25 10. A host transformed with a vector as claimed in  
claim 8 or 9.

11. A host according to claim 10, which is a  
mammalian cell line.

30 12. A process for the preparation of a polypeptide as  
defined in claim 1, which process comprises culturing a  
transformed host as claimed in claim 10 or 11 under such  
conditions that the said polypeptide is expressed.

13. A pharmaceutical composition comprising a  
pharmaceutically acceptable carrier or diluent and, as an

- 25 -

active principle, a polypeptide as claimed in claim 1.

14. A polypeptide as defined in claim 1 for use in the treatment of rheumatoid arthritis.

Fig. 1.


1 ACCA GTGATCTCTA TGCCCGAGTC TCAACCCCTCA ACTGTCAACC CAAGGCACCTT GGGACGTCTT GGACAGACCG  
 75 AGTCCCGGA AGCCCCAGCA CTGCCGCTGC CACACTGCC TGAGCCCAA TGGGGAGTG AGAGGCCATA GCTGTCTGCC  
 40 M G L S T V P D L L L L P L V L L E L L L V G I Y P  
 156 ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG COG CTG GTG CTG GAG CTG TTG GTG GGA ATA TAC CCC  
 16 S G V I G L V P H L G D R E K R D S V C P Q G K  
 228 TCA GGG GTT ATT GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA GAT AGT GTG TGT CCC CAA GGA AAA  
 9 Y I H P Q N N S I C C T K C H K G T Y L Y N D C  
 300 TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT  
 33 P G P G Q D T D C R E C E S G S F T A S E N H L  
 372 CCA GGC CCG GGG CAG GAT ACG GAC TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC  
 57 R H C L S C S K C R K E M G Q V E I S S C T TGC ACA GTG GAC  
 444 AGA CAC TGC CTC AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC CAG TTC  
 81 R D T V C G C R K N Q Y R H Y W S E N L F Q C F  
 516 CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT TTC CAG TGC TTC  
 105 N C S L C L N G T V H L S C Q E K Q N T V C T C  
 558 AAT TGC AGC CTC TGC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG AAA CAG AAC ACC GTG TGC ACC TGC  
 129 H A G F L R E N E C V S C S N C K K S L E C T  
 660 CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG  
 153 K L C L P Q I E N V K G T E D S G T T V L L L P L  
 732 AAG TTG TGC CTA CCC CAG ATT GAG AAT GTT AAG GGC ACT GAG GAC TCA GGC ACC ACA GTG CTG TTG CCC CTG  
 177 V I F F G L C L L S L L F I G L M Y  
 804 GTC ATT TTC TTT GGT CTT TGC CTT TPA TCC CTC CTG TTT GGT TTA ATG TAT CGC TAC CAA CGG TGG AAG  
 201 S K L Y S I V C G K S T P E K E G E L E G T T T  
 876 TCC AAG CTC TAC TCC ATT GTT TGT TGT GGG AAA TCG ACA CCT GAA AAA GAG GGG GAG CTT GAA GGA ACT ACT ACT

Fig. 1(cont.)

225 K P L A P N P S F S P T P G F T L G G F S P V  
 948 AAG CCC CTG GCC CCA AAC CCA AGC TTC AGT CCC ACT CCA GGC TTC ACC CCC ACC CTG GGC TTC AGT CCC GTG  
 249 P S S T F T S S S T Y T P P G D C P N F A A P R R  
 1020 CCC AGT TCC ACC TTC ACC TCC AGC TCC ACC TAT ACC CCC GGT GAC TGT CCC AAC TTT GCG GCT CCC CGC AGA  
 273 E V A P P Y Q G A D P I L A T A L A S D P I P N  
 1092 GAG GTG GCA CCA CCC TAT CAG GGG GCT GAC CCC ATC CTT GCG ACA GCC CTC GCC TCC GAC CCC ATC CCC AAC  
 297 P L Q K W E D S A H K P Q S L D T D D P A T L Y  
 1164 CCC CTT CAG AAG TGG GAG GAC AGT GCC CAC AAG CCA CAG AGC CTA GAC ACT GAT GAC CCC GCG ACG CTG TAC  
 321 A V V E N V P P L R T L E F V R R L G L S D H E  
 1236 GCC GTG GTG GAG AAC GTG CCC CCG TTG CGC TGG AAG GAA TTC GTG CGG CGC CTA GGG CTG AGC GAC CAC GAG  
 345 I D R L E L Q N G R C L R E A Q Y S M L A T W R  
 1308 ATC GAT CGG CTG GAG CTG CAG AAC GGG CGC TGC CTG CGC GAG GCG CAA TAC AGC ATG CTG GCG ACC TGG AGG  
 369 R R T P R R E A T L E L L G R V L R N M D L L G  
 1380 CGG CGC ACG CGG CGC GAG GCC ACG CTG GAG CTG CTG GGA CGC GTG CTC CGC GAC ATG GAC CTG CTG GGC  
 393 C L E D I E E A L C G P A A L P P A P S L L R  
 1452 TGC CTG GAG GAC ATC GAG GAG GCG CTT TGC GGC CCC GCC GCG CTC CCG CCC GCG CCC AGT CTT CTC AGA TGA  
 1521 GGCTGGGCC TGGGGCAGC TCTAAGGACC GTCTCGCAG ATCGCCTTCC AACCCACTT TTTTCTGGAA AGGAGGGGTC  
 1601 CTGACGGGC AAGCAGGAGC TAGCAGCCGC CTACTTGGTG CTAACCCCTC GATGTACATA GCTTTCTCA GCTGCCCTGCG  
 1681 CGCCGCCGAC AGTCAGGCT GTGCGCGCGG AGAGAGGTGC GCCGTGGGCT CAAGAGCCCTG AGTGGGTGGT TTGCGAGGAT  
 1761 GAGGGACGCT ATGCTCATG CCGTTTGG GTGTCTCAC CAGCAAGGCT GCTCGGGGCG CCCTGGTTCG TCCCTGAGCC  
 1841 TTTTTCACAG TGCATAAGCA GTTTTTTG GTTTTGTGT TTTTAA TCAATCATGT TACACTAATA  
 1921 GAAACTTGGC ACTCTGTGC CCTCTGCTG GACAAGCAC ATAGCAAGCT GAACGTGCTT AAGCAGGGG CGAGCACGGA  
 2001 ACAATGGGGC CTTGAGCTGG AGCTGTGGAC TTTTGTACAT ACACTAAAT TCTGAAGTTA AG



2  
 3

3/13

*Fig. 2.*


4113

Fig. 3.



5/13

Fig. 4.



6/13

Fig. 5.





Fig. 13.





7/13

Fig. 6.

First Subdomain

V C P Q G K Y I H P Q N S I C C T K C H K G T Y L Y N D C P G P Q D T D C R  
 T C R L R E Y Y D - Q T A Q M C C S K C S P G Q H A K V F C T K T S - D T V C D  
 A C R E K Q Y L I - - - N S Q C C S L C Q P G G Q K L V S D C T E F T - E T E C L  
 N C V K D T Y P S - - - G H K C C R E C Q P G H G M V S R C D H T R - D T V C H

Second Subdomain

E C - E S G S F T A S E N H L R H C L S C - S K R K E M G Q V E I S S C T V D R D T V C  
 S C - E D S T Y T Q L W N V P E C L S C G S R C - - S S D Q V E T Q A C T R E Q N R I C  
 P C L D N V T F S D V V S A T E P C K P C - T T Y C D P N H R S G S E L K Q N C T P T E D T V C  
 P C G E S E F L D T W N R E - T H C H Q H - K Y C D N H R S G S E L K Q N C T P T E D T V C  
 P C - E P G F Y N E A V N Y - D T C K Q C - T Q C C N H R S G S E L K Q N C T P T E D T V C

Third Subdomain

G C R K N Q Y R H Y W S E N L F Q C F N C S L - - - C L N G T - V H L S C Q E K Q N T V C  
 T C R P G W Y G A L S K - - - Q E G C R L C A P L R K C R P G F G V A R P P G T E T S D V V C K  
 R C A Y G Y Q D E E T - - - G H C E A C S V - - - C E V G S G L V F S C Q D K Q N T V C E  
 T C E E G W H C T S E A - - - C E S C V L H R S C S P G F G V K Q I A T G V S D T T C E

Fourth Subdomain

T C H A G F F L R E N - - - E C V S C S N C K K S L E C T K L C L P Q I E N V K G T  
 P C A P G T F S N T T S S T D I C R P H Q T C N - - - V V A I P G N A S M D A V C T  
 E C P E G T Y S D E A N H V D D P C L P P C T V C E D T E R Q L R E C T P W A - D A E C E  
 P C P P G F F S N V S S A F E K C C H P P W T S C E T K D L V V Q Q A G T N K T D V V C G  
 P C P P G H F S P G S N Q - - - A C C K P P W T N C T L S G K Q I R H P A S N S L D T V C E

8/13

Fig. 7.

DNA sequence	608 b.p.	TGTCTGGCATGG ... CCCAGATTAG	linear
9 / 1		39 / 11	
ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CTG CCG CTG GTG CTC CTG GAG CTG TTG GTG			
met gly leu ser thr val pro asp leu leu leu pro leu val leu leu glu leu val			
69 / 21		99 / 31	
GGA ATA TAC CCC TCA GGG GTT ATT GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA			
gly ile tyr pro ser gly val ile gly leu val pro his leu gly asp arg glu lys arg			
129 / 41		159 / 51	
GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC			
asp ser val cys pro gln gly lys tyr ile his pro gln asn ser ile cys cys thr			
189 / 61		219 / 71	
AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GGG CAG GAT ACG GAC			
lys cys his lys gly thr tyr leu tyr asn asp cys pro gly pro gly gln asp thr asp			
249 / 81		279 / 91	
TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC			
cys arg glu cys glu ser gly ser phe thr ala ser glu asn his leu arg his cys leu			
309 / 101		339 / 111	
AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC			
ser cys ser lys cys arg lys glu met gly gln val glu ile ser ser cys thr val asp			
369 / 121		399 / 131	
CGG GAC ACC GTG TGT GGC TGC AGG AAG AAC CAG TAC CGG CAT TAT TGG AGT GAA AAC CTT			
arg asp thr val cys gly cys arg lys asn gln tyr arg his tyr trp ser glu asn leu			
429 / 141		459 / 151	
TTC CAG TGC TTC AAT TGC AGC CTC TGC CTC AAT GGG ACC GTG CAC CTC TCC TGC CAG GAG			
phe gln cys phe asn cys ser leu cys leu asn gly thr val his leu ser cys gln glu			
489 / 161		519 / 171	
AAA CAG AAC ACC GTG TGC ACC TGC CAT GCA GGT TTC TTT CTA AGA GAA AAC GAG TGT GTC			
lys gln asn thr val cys thr cys his ala gly phe phe leu arg glu asn glu cys val			
549 / 181		579 / 191	
TCC TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT TAG			
ser cys ser asn cys lys lys ser leu glu cys thr lys leu cys leu pro gln ile AMB			

**Fig. 8.**

**SUBSTITUTE SHEET**

10/13

Fig. 9.

DNA sequence	470 b.p.	TGCTGGCATGG ... CCCAGATTAG	linear
9	/	39	/
ATG GGC CTC	TCC ACC GTG CCT GAC CTG CTG	CTG CCG CTG	CTG GAG CTG TTG GTG
met gly leu	ser thr val pro asp leu leu	leu pro leu val leu	leu glu leu leu val
69	/	99	/
GGA ATA TAC	CCC TCA GGG GTT ATT GGA CTG GTC	CCT CAC CTA GGG GAC	AGG GAG AAG AGA
gly ile tyr	pro ser gly val ile gly leu val	pro his leu gly asp arg	glu lys arg
129	/	159	/
GAT AGT GTG	TGT CCC CAA GGA AAA TAT ATC	CAC CCT CAA AAT AAT	TGC ATT TGC TGT ACC
asp ser val	cys pro gln gly lys tyr ile his	pro gln asn asn ser ile	cys cys thr
189	/	219	/
AAG TGC CAC	AAA GGA ACC TAC TTG TAC AAT	GAC TGT CCA GGC CCG	GAG CAG GAT ACG GAC
lys cys his	lys gly thr tyr leu tyr asn	asp cys pro gly pro gly	asp thr asp
249	/	279	/
TGC AGG AAG	AAC CAG TAC CGG CAT TAT TGG	AGT GAA AAC CTT TTC	CAG TGC TTC AAT TGC
cys arg lys	asn gln tyr arg his tyr trp	ser glu asn leu phe	gln cys phe asn cys
309	/	339	/
AGC CTC TGC	CTC AAT GGG ACC GTG CAC CTC	TCC TGC CAG GAG AAA	CAG AAC ACC GTG TGC
ser leu cys	leu asn gly thr val his leu	ser cys gln glu lys	gln asn thr val cys
369	/	399	/
ACC TGC CAT	GCA GGT TTC TTT CTA AGA GAA	AAC GAG TGT GTC TCC	TGT AGT AAC TGT AAG
thr cys his	ala gly phe leu arg glu	asn glu cys val	ser cys ser asn cys
429	/	459	/
AAA AGC CTG	GAG TGC ACG AAG TTG TGC CTA	CCC CAG ATT TAG	
lys ser leu	glu cys thr lys leu cys	leu pro gln ile	AMB

11/13



**Fig. 10.**

DNA sequence	485 b.p.	TGCTGGCATGG ... CCCAGATTAG	linear
9 / 1	39 / 11		
ATG GGC CTC TCC ACC GTG CCT GAC CTG CTG CCG CTG CTG GAG CTG TTG GTG			
met gly leu ser thr val pro asp leu leu pro leu val leu leu glu leu val			
69 / 21	99 / 31		
GGA ATA TAC CCC TCA GGG GTT ATT GGA CTG GTC CCT CAC CTA GGG GAC AGG GAG AAG AGA			
gly ile tyr pro ser gly val ile gly leu val pro his leu gly asp arg glu lys arg			
129 / 41	159 / 51		
GAT AGT GTG TGT CCC CAA GGA AAA TAT ATC CAC CCT CAA AAT AAT TCG ATT TGC TGT ACC			
asp ser val cys pro gln gly lys tyr ile his pro gln asn asn ser ile cys cys thr			
189 / 61	219 / 71		
AAG TGC CAC AAA GGA ACC TAC TTG TAC AAT GAC TGT CCA GGC CCG GAG GAT ACG GAC			
lys cys his lys gly thr tyr leu tyr asn asp cys pro gly pro gly gln asp thr asp			
249 / 81	279 / 91		
TGC AGG GAG TGT GAG AGC GGC TCC TTC ACC GCT TCA GAA AAC CAC CTC AGA CAC TGC CTC			
cys arg glu cys glu ser gly ser phe thr ala ser glu asn his leu arg his cys leu			
309 / 101	339 / 111		
AGC TGC TCC AAA TGC CGA AAG GAA ATG GGT CAG GTG GAG ATC TCT TCT TGC ACA GTG GAC			
ser cys ser lys cys arg lys glu met gly gln val glu ile ser ser cys thr val asp			
369 / 121	399 / 131		
CGG GAC ACC GTG TGT ACC TGC CAT GCA GGT TTC TTC CTA AGA GAA AAC GAG TGT GTC TCC			
arg asp thr val cys thr cys his ala gly phe leu arg glu asn glu cys val ser			
429 / 141	459 / 151		
TGT AGT AAC TGT AAG AAA AGC CTG GAG TGC ACG AAG TTG TGC CTA CCC CAG ATT TAG			
cys ser asn cys lys lys ser leu glu cys thr lys leu cys leu pro gln ile AMB			



13/13

Fig.12.



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 91/01826

**I. CLASSIFICATION OF SUBJECT MATTER** (If several classification symbols apply, indicate all)<sup>6</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C12N15/12; C07K13/00; A61K37/02

**II. FIELDS SEARCHED**Minimum Documentation Searched<sup>7</sup>

Classification System	Classification Symbols
Int.Cl. 5	C07K

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched<sup>8</sup>**III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup>**

Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	EP,A,0 308 378 (YEDA RESEARCH AND DEVELOPMENT COMPANY, LIMITED) 22 March 1989 see the whole document ---	1-14
X	CELL. vol. 61, 20 April 1990, CAMBRIDGE, MA US pages 351 - 359; Shall, T.J. et al.: 'Molecular cloning and expression of the human 55Kd tumor necrosis factor receptor.' see the whole document ---	1-14
X	CELL. vol. 61, 20 April 1990, CAMBRIDGE, MA US pages 361 - 370; Loetscher, H. et al.: 'Molecular cloning and expression of a receptor for human tumor necrosis factor.' see the whole document --- -/-	1-14

<sup>9</sup> Special categories of cited documents: <sup>10</sup>

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

<sup>11</sup> Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<sup>12</sup> document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step<sup>13</sup> document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.<sup>14</sup> document member of the same patent family**IV. CERTIFICATION**

Date of the Actual Completion of the International Search

23 JANUARY 1992

Date of Mailing of this International Search Report

06.02.92

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

NAUCHE S.A.



III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA. vol. 87, 1 October 1990, WASHINGTON US pages 7380 - 7384; Gray, Patrick W.; Barrett, Kathy; Chantry, David; Turner, Martin; Feldmann, Marc: 'Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein' see the whole document ---	1-14
P,X	EP,A,0 393 438 (BOEHRINGER INGELHEIM INTERNATIONAL) 24 October 1990 see the whole document ---	1-14

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO. GB 9101826  
SA 52300**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 23/01/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0308378	22-03-89	AU-A- 2206888 JP-A- 2000200	16-03-89 05-01-90
-----			
EP-A-0393438	24-10-90	DE-A- 3913101 DE-A- 3920282 JP-A- 3164179	31-10-90 03-01-91 16-07-91
-----			

FIG. 4A

	1	50
huCHD	MPSLPAPPAPLLLLLGLLLGSRPARGAGPEPPVLP	IRSEKEPLPVRGAAG
huCHL	---MGGMKYIFSLFFLLLEG-----	GKTEQVKHSETY
huCHL2	--MVPEVRVLSSLEGLALLWFP-----	LDSHARARPDMF
	51	100
huCHD	CTFGGKVYALDETWHEDLGEPPFGVMRCVLCACEAPQWGRRT	RGPGRVSC
huCHL	CMEQDKKYRVGERWHPYL-EPYGLVYCVNCICSENGNVLCSR-----	
huCHL2	CLFHGKRYSPGESWHPYL-EPQGLMYCLRCTCSEGAHVSCYR-----	
	101	150
huCHD	NIKPECHTPAGGQPRQLPGHCCQTCPOERSSSSERQPSGLSFEYPRDPEHR	
huCHL	--VRCENVHCLSPVHTPHLCGPRCPEDSLPPVN---	NKVTSKSCEYNG
huCHL2	---LHCPPVHCPOEVTEPQCCPKGVEPHTPSG----	LRAPPKSCOING
	151	200
huCHD	SYSDRGEPGAEEERARGDHTDFVALLTGPRSQAVARARVSLLRSSLRFSI	
huCHL	TTYQHGEIFVAEGLFQNRQPNQCTQCSCSEG-----	
huCHL2	TMYQHGEIFSAHELFP SRLPNQCVLCSCTEG-----	
	201	250
huCHD	SYRRLDRPTRIRFSDSNGLSVLFEHPAAPTQDGLVCGVWRAVPRLSLRLLR	
huCHL	-----NYYCGLKTCPKLTCAFPVSVDPDCCRCVCRGDG-ELSW	
huCHL2	-----QTYCGLTTCPEPGCPAPLPLPDSCCQACKDEASEQSD	
	251	300
huCHD	AEQLHVALVTLTHPSGEVWGPLIRHRLAETFSAILTLEGPPQOGVGGI	
huCHL	EHSDGDI FRQPANREARHSYHRSHYDPPPSRQAGGLSRFP-----	
huCHL2	EEDSVQSLHGVRHPQDPCSSDAGRKRGPPTPAPTGLS-----	
	301	350
huCHD	TLLTSLDTEDSLHFLLLFRGLLEPRSGGLTOVPLRLQILHOGQLIRELQA	
huCHL	-----GARSHRGALMDSQQASGTIVQIVINNKHKHGQVCVSNG	
huCHL2	-----APLSFIPRHFRPKGAGSTTVKIVLKEKHKK--ACVHGG	
	351	400
huCHD	NVSAQEPGFAEVLPNLTVQEMDWLVLGELQMALEWAGRPGLRISGHIAAR	
huCHL	KTYSHGESWHPNLRAFGIVIECVLCTCNVTKECKKHCPNRYPCKYPOKI	
huCHL2	KTYSHGEVWHPAFRAFGPIPCILCTCEDGRDCORVTCPTTEYPCRHPKVI	
	401	450
huCHD	KSCDVLQSVLCGADALIEVOTGAAGSASLTLLGNGSLIYQVQVVGTSSEV	
huCHL	DGKCKKCPGKKAKEELGQSFDNKGYFCGEETMPMYESVFMEDGETTRK	
huCHL2	AGKCKKICP---EDKADGKHSEISSSTRCPKAPGRVLVHTSVSPSPDNLRR	
	451	500
huCHD	VAMTLETKPQRDQRTVLCHMAGLQPGHTAVGICPGLGARGAHMLQNE	
huCHL	IALETERPPQ-----VEVHVWTTIRKG-----	ILQHF
huCHL2	FALHEHASDL-----METYTWKLVKG-----	IFHLT

FIG. 4B

	501	550
huCHD	LFLNVGTDKDFPDGELRGHVAALPYCGHSARHDTLPVPLAGALVLPVVKSQ	
huCHL	HIEKISKR-MFEELPHFKLVTRTTLSQWKIFTTEGEAQISOMCSSRVCRTTE	
huCHL2	QIKKVRKQDFQKEAQHFRLLAGPHEGHWNVFLAQTLELKVTASPDKVTKT	
	551	600
huCHD	AAGHAWISLDTHCHLHYEVLLAGLGGSEQGTVTAHLLGPPGTPGPRRLLK	
huCHL	LEDLVKLYLYLERSEKGC-----	
huCHL2	-----	
	601	650
huCHD	GFYGSEAQGVVKDLEPELLRHLAKGMASLLITTKGSPRGELRGQVHIANQ	
huCHL	-----	
huCHL2	-----	
	651	700
huCHD	CEVGGLRLEAAGAEGVPLAPDTASAAPPVVPGLPALAPAKPGGPGRPR	
huCHL	-----	
huCHL2	-----	
	701	750
huCHD	DPNTCFFEGQQRPHGARWAPNYDPLCSLCTCQRRTVICDPVVCPPSPCPH	
huCHL	-----	
huCHL2	-----	
	751	800
huCHD	PVQAPDQCCPVCPEKQDVRDLPGLPFRSRDPGEGCYFDGDRSWRAAGTRWH	
huCHL	-----	
huCHL2	-----	
	801	850
huCHD	PVVPPFGLIKCAVCTCKGGTGEVHCEKVQCPRLACAQPVRVNPTDCCCKQC	
huCHL	-----	
huCHL2	-----	
	851	900
huCHD	PVGSGAHPQLGDPMQSGCRFAGQWFPESQSWHPSVPPFPGEMSCITC	
huCHL	-----	
huCHL2	-----	
	901	950
huCHD	RCGAGVPHCERDDCSLPLSCGSGKESRCCSRCTAHRRPAPETRTRDPELEK	
huCHL	-----	
huCHL2	-----	
	951	
huCHD	EAEGS	
huCHL	-----	
huCHL2	-----	